SecBot SecBot
S-3 ·Filed Jun 2, 2026

FBRX

Forte Biosciences, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed5mo ago SEC0001193125-26-253668
Shelf registration, potential dilution
Actionable Insight ▼ Bearish

The shelf filing itself is not an immediate dilutive event, but the accelerating cash burn ($22M quarterly loss) and declining cash position ($58.2M) make it highly likely the company will tap this shelf soon. Monitor for a prospectus supplement announcing a specific offering, that will be the actual dilutive event. The 91% analyst bullishness is at odds with the deteriorating cash position; expect downward estimate revisions if a dilutive offering materializes.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$17.00
T+0 close · Jun 2, 2026 · via day close
Latest settled
+352.88%
T+60 · $76.99
Vs SPY
+350.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 3 $17.00entry
  2. T+1 · 6mo ago −1.82%α −2.22% · $16.69
  3. T+5 · 5mo ago −1.06%α +2.76% · $16.82
  4. T+20 · 5mo ago +23.06%α +24.06% · $20.92
  5. T+60 · 3mo ago +352.88%α +350.38% · $76.99
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Forte Biosciences filed a universal shelf registration statement on Form S-3 to offer and sell up to $500,000,000 in securities (common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts, and units) from time to time. The company has a market cap of $342M, meaning the shelf represents ~146% of current market cap, signaling massive potential dilution. The filing is a placeholder, no specific offering is announced, but the company's cash burn is accelerating (Q1 2026 net loss of $22.1M vs $15.7M a year ago), and cash & equivalents fell from $77.0M to $58.2M in Q1 2026, suggesting the company will likely tap this shelf soon to fund operations.

Key Financial Metrics

Offering Size
$500.0M

Key Facts

  • Shelf registration for up to $500,000,000 in securities, ~146% of current $342M market cap
  • Cash & equivalents declined from $77.0M (Dec 2025) to $58.2M (Mar 2026)
  • Q1 2026 net loss of $22.1M vs $15.7M in Q1 2025, burn rate accelerating
  • Operating expenses rose 39% YoY to $22.4M, driven by R&D spend of $20.3M
  • Accumulated deficit grew to $245.5M as of March 31, 2026
  • No specific offering announced, shelf is a forward-looking capital-raising mechanism
  • Company is a clinical-stage biopharma with no approved products or revenue
  • Prior shelf (File No. 333-286226) had $50.7M in unsold securities carried forward into this filing

Financial Impact

Shelf of $500M represents ~146% dilution vs current $342M market cap; cash burn of ~$22M/quarter implies ~2.6 quarters of runway at current cash level of $58.2M

dilutioncash runwayshare count

Risk Factors

  • Massive potential dilution, shelf is 146% of current market cap
  • Accelerating cash burn with no approved products or revenue
  • Clinical-stage biotech with binary pipeline risk (Phase 2 celiac data expected 2026)
  • Prior shelf carry-forward of $50.7M suggests previous capital raises were insufficient

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001193125-26-253668
Document: d117004dex43.htm0001193125-26-253668
Document: d117004dexfilingfees.htm0001193125-26-253668
Document: d117004dex51.htm0001193125-26-253668

Track record

15 reports on FBRX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  3. Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
  4. Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
  5. Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
  6. Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
  7. Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
  8. Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
  9. Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
  10. Jun 2, 202623w ago S-3 Bearish 6/10 Viewing Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (10h 55m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026